Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 3/2023

01-04-2023 | Thrombectomy | Review

Combined Therapeutics: Future Opportunities for Co-therapy with Thrombectomy

Authors: Phavalan Rajendram, Asad Ikram, Marc Fisher

Published in: Neurotherapeutics | Issue 3/2023

Login to get access

Abstract

Stroke is an urgent public health issue with millions of patients worldwide living with its devastating effects. The advent of thrombolysis and endovascular thrombectomy has transformed the hyperacute care of these patients. However, a significant proportion of patients receiving these therapies still goes on to have unfavorable outcomes and many more remain ineligible for these therapies based on our current guidelines. The future of stroke care will depend on an expansion of the scope of thrombolysis and endovascular thrombectomy to patients outside traditional time windows, more distal occlusions, and large vessel occlusions with mild clinical deficits, for whom clinical trial results have not proven therapeutic efficacy. Novel cytoprotective therapies targeting the ischemic cascade and reperfusion injury therapy, in combination with our existing treatment modalities, should be explored to further improve outcomes for these patients with acute ischemic stroke. In this review, we will review the current status of thrombolysis and thrombectomy, suggest additional data that is needed to enhance these therapies, and discuss how cytoprotection might be combined with thrombectomy.
Appendix
Available only for authorised users
Literature
1.
Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022;17(1):18–29.PubMedCrossRef
2.
Smith WS, Lev MH, English JD, Camargo EC, Chou M, Johnston SC, et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke. 2009;40(12):3834–40.PubMedPubMedCentralCrossRef
3.
Adeoye O, Albright KC, Carr BG, Wolff C, Mullen MT, Abruzzo T, et al. Geographic access to acute stroke care in the United States. Stroke. 2014;45(10):3019–24.PubMedPubMedCentralCrossRef
4.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31.PubMedCrossRef
5.
Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.PubMedCrossRef
6.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.PubMedCrossRef
7.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.PubMedCrossRef
8.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.PubMedCrossRef
9.
Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.PubMedCrossRef
10.
Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15(11):1138–47.PubMedCrossRef
11.
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.PubMedCrossRef
12.
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.PubMedPubMedCentralCrossRef
13.
Jovin TG, Nogueira RG, Lansberg MG, Demchuk AM, Martins SO, Mocco J, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. Lancet. 2022;399(10321):249–58.PubMedCrossRef
14.
Ikram A, Farooqui M, Suriya S, Quadri SA, Zafar A. Smog sign: hazy diffusion-weighted imaging restriction in dense axonal tracts in the pons on hyperacute MRI with remarkable clinical improvement after intra-arterial thrombectomy. Cureus. 2019;11(8):e5461.PubMedPubMedCentral
15.
Langezaal LCM, van der Hoeven E, Mont’Alverne FJA, de Carvalho JJF, Lima FO, Dippel DWJ, et al. Endovascular therapy for stroke due to basilar-artery occlusion. N Engl J Med. 2021;384(20):1910–20.PubMedCrossRef
16.
Liu X, Dai Q, Ye R, Zi W, Liu Y, Wang H, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. 2020;19(2):115–22.PubMedCrossRef
17.
Jovin TG, Li C, Wu L, Wu C, Chen J, Jiang C, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med. 2022;387(15):1373–84.PubMedCrossRef
18.
Tao C, Nogueira RG, Zhu Y, Sun J, Han H, Yuan G, et al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med. 2022;387(15):1361–72.PubMedCrossRef
19.
Chen JH, Hong CT, Chung CC, Kuan YC, Chan L. Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta-analysis. Thromb J. 2022;20(1):35.PubMedPubMedCentralCrossRef
20.
Almallouhi E, Al Kasab S, Hubbard Z, Bass EC, Porto G, Alawieh A, et al. Outcomes of mechanical thrombectomy for patients with stroke presenting with low alberta stroke program early computed tomography score in the early and extended window. JAMA Netw Open. 2021;4(12):e2137708.PubMedPubMedCentralCrossRef
21.
Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023.
22.
Huo X, Ma G, Tong X, Zhang X, Pan Y, Nguyen TN, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct. N Engl J Med. 2023.
23.
Volny O, Zerna C, Tomek A, Bar M, Rocek M, Padr R, et al. Thrombectomy vs medical management in low NIHSS acute anterior circulation stroke. Neurology. 2020;95(24):e3364–72.PubMedPubMedCentralCrossRef
24.
Kim BJ, Menon BK, Yoo J, Han JH, Kim BJ, Kim CK, et al. Effectiveness and safety of EVT in patients with acute LVO and low NIHSS. Front Neurol. 2022;13:955725.PubMedPubMedCentralCrossRef
25.
Feil K, Matusevicius M, Herzberg M, Tiedt S, Kupper C, Wischmann J, et al. Minor stroke in large vessel occlusion: a matched analysis of patients from the German Stroke Registry-Endovascular Treatment (GSR-ET) and patients from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Eur J Neurol. 2022;29(6):1619–29.PubMedPubMedCentralCrossRef
26.
27.
Yeo LLL, Jing M, Bhogal P, Tu T, Gopinathan A, Yang C, et al. Evidence-based updates to thrombectomy: targets, new techniques, and devices. Front Neurol. 2021;12:712527.PubMedPubMedCentralCrossRef
28.
NINDS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef
29.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
30.
English JD, Yavagal DR, Gupta R, Janardhan V, Zaidat OO, Xavier AR, et al. Mechanical thrombectomy-ready comprehensive stroke center requirements and endovascular stroke systems of care: recommendations from the endovascular stroke standards committee of the society of vascular and interventional neurology (SVIN). Interv Neurol. 2016;4(3–4):138–50.PubMedPubMedCentral
31.
Masoud HE, de Havenon A, Castonguay AC, Asif KS, Nguyen TN, Mehta B, et al. 2022 Brief Practice update on intravenous thrombolysis before thrombectomy in patients with large vessel occlusion acute ischemic stroke: a statement from society of vascular and interventional neurology guidelines and practice standards (GAPS) committee. Stroke Vasc Interv Neurol. 2022;2(4):e000276.
32.
Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M, Kanazawa R, Takayama Y, et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial. JAMA. 2021;325(3):244–53.PubMedPubMedCentralCrossRef
33.
LeCouffe NE, Kappelhof M, Treurniet KM, Rinkel LA, Bruggeman AE, Berkhemer OA, et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke. N Engl J Med. 2021;385(20):1833–44.PubMedCrossRef
34.
Yang P, Zhang Y, Zhang L, Zhang Y, Treurniet KM, Chen W, et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med. 2020;382(21):1981–93.PubMedCrossRef
35.
Meinel TR, Kaesmacher J, Buetikofer L, Strbian D, Eker OF, Cognard C, et al. Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial. J Neurointerv Surg. 2022.
36.
Mitchell PJ, Yan B, Churilov L, Dowling RJ, Bush SJ, Bivard A, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet. 2022;400(10346):116–25.PubMedCrossRef
37.
Roaldsen MB, Jusufovic M, Berge E, Lindekleiv H. Endovascular thrombectomy and intra-arterial interventions for acute ischaemic stroke. Cochrane Database Syst Rev. 2021;6:CD007574.PubMed
38.
Renu A, Millan M, San Roman L, Blasco J, Marti-Fabregas J, Terceno M, et al. Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: the CHOICE randomized clinical trial. JAMA. 2022;327(9):826–35.PubMedCrossRef
39.
Huang X, MacIsaac R, Thompson JL, Levin B, Buchsbaum R, Haley EC Jr, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534–43.PubMedCrossRef
40.
Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161–9.PubMedCrossRef
41.
Zhu A, Rajendram P, Tseng E, Coutts SB, Yu AYX. Alteplase or tenecteplase for thrombolysis in ischemic stroke: an illustrated review. Res Pract Thromb Haemost. 2022;6(6):e12795.PubMedPubMedCentralCrossRef
42.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–82.PubMedCrossRef
43.
Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol. 2022;21(6):520–7.PubMedCrossRef
44.
Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645–54.PubMedCrossRef
45.
46.
47.
Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46(3):769–74.PubMedCrossRef
48.
49.
Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke. 1981;12(6):723–5.PubMedCrossRef
50.
Xie Y, Oppenheim C, Guillemin F, Gautheron V, Gory B, Raoult H, et al. Pretreatment lesional volume impacts clinical outcome and thrombectomy efficacy. Ann Neurol. 2018;83(1):178–85.PubMedCrossRef
51.
Baron JC. Protecting the ischaemic penumbra as an adjunct to thrombectomy for acute stroke. Nat Rev Neurol. 2018;14(6):325–37.PubMedCrossRef
52.
53.
54.
Felberg RA, Burgin WS, Grotta JC. Neuroprotection and the ischemic cascade. CNS Spectr. 2000;5(3):52–8.PubMedCrossRef
55.
Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era. Nat Rev Neurol. 2022;18(4):193–202.PubMedPubMedCentralCrossRef
56.
Cui H, Hayashi A, Sun HS, Belmares MP, Cobey C, Phan T, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007;27(37):9901–15.PubMedPubMedCentralCrossRef
57.
Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999;284(5421):1845–8.PubMedCrossRef
58.
Bai J, Lyden PD. Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. Int J Stroke. 2015;10(2):143–52.PubMedCrossRef
59.
Khatri R, McKinney AM, Swenson B, Janardhan V. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology. 2012;79(13 Suppl 1):S52–7.PubMedCrossRef
60.
Piccardi B, Arba F, Nesi M, Palumbo V, Nencini P, Giusti B, et al. Reperfusion injury after ischemic stroke study (RISKS): single-centre (Florence, Italy), prospective observational protocol study. BMJ Open. 2018;8(5):e021183.PubMedPubMedCentralCrossRef
61.
Suzuki Y, Nagai N, Umemura K. A review of the mechanisms of blood-brain barrier permeability by tissue-type plasminogen activator treatment for cerebral ischemia. Front Cell Neurosci. 2016;10:2.PubMedPubMedCentralCrossRef
62.
Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke. 2013;44(10):2901–3.PubMedCrossRef
63.
Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci. 2016;10:56.PubMedPubMedCentralCrossRef
64.
Takamatsu H, Tsukada H, Kakiuchi T, Nishiyama S, Noda A, Umemura K. Detection of reperfusion injury using PET in a monkey model of cerebral ischemia. J Nucl Med. 2000;41(8):1409–16.PubMed
65.
Ames A III, Wright RL, Kowada M, Thurston JM, Majno G. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol. 1968;52(2):437–53.PubMedPubMedCentral
66.
Crowell RM, Olsson Y. Impaired microvascular filling after focal cerebral ischemia in the monkey. Modification by treatment. Neurology. 1972;22(5):500–4.PubMedCrossRef
67.
Kloner RA, King KS, Harrington MG. No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018;315(3):H550–62.PubMedCrossRef
68.
69.
Puig J, Shankar J, Liebeskind D, Terceno M, Nael K, Demchuk AM, et al. From time is brain” to “imaging is brain: a paradigm shift in the management of acute ischemic stroke. J Neuroimaging. 2020;30(5):562–71.PubMedCrossRef
70.
Farzin B, Fahed R, Guilbert F, Poppe AY, Daneault N, Durocher AP, et al. Early CT changes in patients admitted for thrombectomy: intrarater and interrater agreement. Neurology. 2016;87(3):249–56.PubMedPubMedCentralCrossRef
71.
Sheth SA, Liebeskind DS. Imaging evaluation of collaterals in the brain: physiology and clinical translation. Curr Radiol Rep. 2014;2(1):29.PubMedCrossRef
72.
Campbell BC, Christensen S, Tress BM, Churilov L, Desmond PM, Parsons MW, et al. Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab. 2013;33(8):1168–72.PubMedPubMedCentralCrossRef
73.
Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184(1–2):53–68.PubMedCrossRef
74.
El Amki M, Gluck C, Binder N, Middleham W, Wyss MT, Weiss T, et al. Neutrophils obstructing brain capillaries are a major cause of no-reflow in ischemic stroke. Cell Rep. 2020;33(2):108260.PubMedCrossRef
75.
Kraft P, Gob E, Schuhmann MK, Gobel K, Deppermann C, Thielmann I, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44(11):3202–10.PubMedCrossRef
76.
Schuhmann MK, Krstic M, Kleinschnitz C, Fluri F. Fingolimod (FTY720) Reduces cortical infarction and neurological deficits during ischemic stroke through potential maintenance of microvascular patency. Curr Neurovasc Res. 2016;13(4):277–82.PubMedCrossRef
77.
Tian DC, Shi K, Zhu Z, Yao J, Yang X, Su L, et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. Ann Neurol. 2018;84(5):717–28.PubMedPubMedCentralCrossRef
78.
Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009;37(7 Suppl):S186–202.PubMedCrossRef
79.
van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain. 2007;130(Pt 12):3063–74.PubMedCrossRef
80.
Kuczynski AM, Marzoughi S, Al Sultan AS, Colbourne F, Menon BK, van Es A, et al. Therapeutic hypothermia in acute ischemic stroke-a systematic review and meta-analysis. Curr Neurol Neurosci Rep. 2020;20(5):13.PubMedCrossRef
81.
Zhao H, Steinberg G. Limited therapeutic time windows of mild-to-moderate hypothermia in a focal ischemia model in rat. Stroke Res Treat. 2011;2011:131834.PubMedPubMedCentral
82.
Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395(10227):878–87.PubMedCrossRef
83.
Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke. 2008;39(9):2544–53.PubMedCrossRef
84.
Tymianski M. Combining neuroprotection with endovascular treatment of acute stroke: is there hope? Stroke. 2017;48(6):1700–5.PubMedCrossRef
85.
Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11(11):942–50.PubMedCrossRef
86.
Mayor-Nunez D, Ji Z, Sun X, Teves L, Garman JD, Tymianski M. Plasmin-resistant PSD-95 inhibitors resolve effect-modifying drug-drug interactions between alteplase and nerinetide in acute stroke. Sci Transl Med. 2021;13(588).
87.
Hernandez-Enriquez M, Abad-Santos F, Cotgreave I, Gallego J Sr, Jilma B, Flores AF, et al., editors. LB2 - April: a double-blind, placebo-controlled, randomized, phase Ib/IIa clinical study of aptoll for the treatment of acute ischemic stroke. International Stroke Conference; 2023 February 8, 2023; Dallas, Texas.
88.
Hong JM, Lee JS, Lee YB, Shin DH, Shin DI, Hwang YH, et al. Nelonemdaz for patients with acute ischemic stroke undergoing endovascular reperfusion therapy: a randomized phase II trial. Stroke. 2022;53(11):3250–9.PubMedPubMedCentralCrossRef
89.
Li W, Qi Z, Ma Q, Ding J, Wu C, Song H, et al. Normobaric hyperoxia combined with endovascular treatment for patients with acute ischemic stroke: a randomized controlled clinical trial. Neurology. 2022;99(8):e824–34.PubMedCrossRef
90.
Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Marti-Fabregas J, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13(5):453–60.PubMedCrossRef
91.
Sansing L, editor. Primary results of the stroke prediction assessment network. International Stroke Conference; 2023 February 8, 2023; Dallas, Texas.
92.
Chamorro A, Lo EH, Renu A, van Leyen K, Lyden PD. The future of neuroprotection in stroke. J Neurol Neurosurg Psychiatry. 2021;92(2):129–35.PubMedCrossRef
93.
Savitz SI, Baron JC, Fisher M, STAIR X Consortium. Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era. Stroke. 2019;50(4):1026–31.PubMedCrossRef
94.
Rocha M, Desai SM, Jadhav AP, Jovin TG. Prevalence and temporal distribution of fast and slow progressors of infarct growth in large vessel occlusion stroke. Stroke. 2019;50(8):2238–40.PubMedCrossRef
95.
Wu TC, Sarraj A, Jacobs A, Shen L, Indupuru H, Biscamp D, et al. Telemedicine-guided remote enrollment of patients into an acute stroke trial. Ann Clin Transl Neurol. 2015;2(1):38–42.PubMedCrossRef
96.
Cooray C, Fekete K, Mikulik R, Lees KR, Wahlgren N, Ahmed N. Threshold for NIH stroke scale in predicting vessel occlusion and functional outcome after stroke thrombolysis. Int J Stroke. 2015;10(6):822–9.PubMedCrossRef
97.
Sergot PB, Maza AJ, Derrick BJ, Smith LM, Berti LT, Wilcox MR, et al. Portable Neuromonitoring device detects large vessel occlusion in suspected acute ischemic stroke. Stroke. 2021;52(4):1437–40.PubMedCrossRef
98.
Ebinger M, Siegerink B, Kunz A, Wendt M, Weber JE, Schwabauer E, et al. Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin. JAMA. 2021;325(5):454–66.PubMedPubMedCentralCrossRef
99.
Kerr DM, Fulton RL, Lees KR, Collaborators V. Seven-day NIHSS is a sensitive outcome measure for exploratory clinical trials in acute stroke: evidence from the Virtual International Stroke Trials Archive. Stroke. 2012;43(5):1401–3.PubMedCrossRef
Metadata
Title
Combined Therapeutics: Future Opportunities for Co-therapy with Thrombectomy
Authors
Phavalan Rajendram
Asad Ikram
Marc Fisher
Publication date
01-04-2023
Publisher
Springer International Publishing
Published in
Neurotherapeutics / Issue 3/2023
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-023-01369-1

Other articles of this Issue 3/2023

Neurotherapeutics 3/2023 Go to the issue

Original Article

BDNF Augmentation Using Riluzole Reverses Doxorubicin-Induced Decline in Cognitive Function and Neurogenesis

Original Article

Cell-Specific Expression of Human SIRT1 by Gene Therapy Reduces Retinal Ganglion Cell Loss Induced by Elevated Intraocular Pressure

Review

The Future of Ischemic Stroke Diagnosis and a Review of Underrecognized Ischemic Stroke Etiologies

Review

Evolving Thrombolytics: from Alteplase to Tenecteplase

Original Article

Acute Treatment with the M-Channel (Kv7, KCNQ) Opener Retigabine Reduces the Long-Term Effects of Repetitive Blast Traumatic Brain Injuries

Review

Hemorrhagic Conversion of Acute Ischemic Stroke